Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Validation of suPAR turbidimetric assay on Cobas® (c502 and c702) and comparison to suPAR ELISA

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Quantification of biotin in plasma samples by column switching liquid chromatography - tandem mass spectrometry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prognostic utility of serum YKL-40 in patients with cervical cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Estimation of the celiac disease prevalence in Denmark and the diagnostic value of HLA-DQ2/DQ8

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Circadian variations in plasma concentrations of cholecystokinin and gastrin in man

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Leukocyte Activation Profile Assessed by Raman Spectroscopy Helps Diagnosing Infection and Sepsis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. An open label trial of anakinra to prevent respiratory failure in COVID-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

suPAR is a plasma marker of chronic inflammation, and an elevated suPAR is consistently associated with worse outcome in a variety of clinical conditions. Quantification of suPAR is useful for determining patient risk in triage, but there is no fast automatized method for quick determination of suPAR. We developed and validated a rapid latex particle-enhanced turbidimetric immunoassay for quantification of plasma suPAR on the c502 and the c702 Roche Cobas® 8000 measurment systems. The turbidimetric assay was validated against the suPARnostic® ELISA (ViroGates, Denmark). This validation demonstrates suPAR can be analysed by turbidimetry giving very similar results (<15% difference) compared to the ELISA method and the observed correlations (n = 103) were strong, r > 0.95. Roche Cobas® 8000 instruments demonstrated repeatability and repoducibility, CV % at 3.4-4.1 and 5.7-11.4, respectively. The estimated limit of detection was 1.30 µg/L and 1.31 µg/L for the Cobas® c502 and c702, respectively. Dilution tests showed linearity of suPAR from 1.8 to 26.5 μg/L. The acceptable concentrations of Bilirubin, Intralipid and Hemoglobin, were 350 µmol/L, 3.3 g/L and 1.4 g/L, respectively. suPAR can be quantified reproducibly within 10 min using a turbidimetry assay. This assay is faster than ELISA with similar results, making it suitable for clinical routine analysis.

OriginalsprogEngelsk
TidsskriftScandinavian Journal of Clinical and Laboratory Investigation
Vol/bind80
Udgave nummer4
Sider (fra-til)327-335
Antal sider9
ISSN0036-5513
DOI
StatusUdgivet - jul. 2020

ID: 59613983